| 1 |
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin et al. · New England Journal of Medicine
Open access |
28 Sep 2019 |
3,784 |
| 2 |
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine
Open access |
4 Jun 2017 |
3,322 |
| 3 |
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al. · The Lancet
|
25 Jun 2012 |
3,009 |
| 4 |
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael James Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology
Open access |
19 Jul 2017 |
2,883 |
| 5 |
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Vincenzo Bronte, Sven Brandau, Shu‐Hsia Chen et al. · Nature Communications
Open access |
6 Jul 2016 |
2,806 |
| 6 |
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al. · New England Journal of Medicine
Open access |
16 Nov 2014 |
2,718 |
| 7 |
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva M. Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine
Open access |
15 May 2019 |
2,660 |
| 8 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew Xiuxuan Zhu et al. · The Lancet Oncology
|
3 Jun 2018 |
2,555 |
| 9 |
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa et al. · New England Journal of Medicine
Open access |
4 Jul 2018 |
2,386 |
| 10 |
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman, Giacomo Desantis, Bassam Janji et al. · The Journal of Experimental Medicine
Open access |
28 Apr 2014 |
2,205 |
| 11 |
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Michael James Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology
Open access |
20 Jan 2018 |
2,121 |
| 12 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 13 |
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Yi-Long Lung Cancer Wu et al. · New England Journal of Medicine
Open access |
19 Sep 2020 |
1,809 |
| 14 |
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
3 Mar 2021 |
1,801 |
| 15 |
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz et al. · New England Journal of Medicine
Open access |
30 Sep 2019 |
1,500 |
| 16 |
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez et al. · The Lancet Oncology
|
22 Oct 2018 |
1,426 |
| 17 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long et al. · The Lancet
|
31 May 2015 |
1,419 |
| 18 |
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries et al. · New England Journal of Medicine
Open access |
7 Jun 2017 |
1,415 |
| 19 |
The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells
Michelangelo Cordenonsi, Francesca Zanconato, Luca Azzolin et al. · Cell
Open access |
Nov 2011 |
1,415 |
| 20 |
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert et al. · New England Journal of Medicine
Open access |
4 Jun 2019 |
1,412 |
| 21 |
Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Francesca Zanconato, Mattia Forcato, Giusy Battilana et al. · Nature Cell Biology
Open access |
10 Aug 2015 |
1,309 |
| 22 |
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al. · The Lancet
Open access |
17 Dec 2015 |
1,288 |
| 23 |
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M.M. Eggermont et al. · The Lancet Oncology
|
5 Apr 2015 |
1,266 |
| 24 |
Altered macrophage differentiation and immune dysfunction in tumor development
Antonio Sica, Vincenzo Bronte · Journal of Clinical Investigation
Open access |
May 2007 |
1,247 |
| 25 |
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al. · Journal of Clinical Oncology
Open access |
24 Nov 2021 |
1,144 |
| 26 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology
Open access |
31 Aug 2015 |
1,111 |
| 27 |
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer, Paolo A. Ascierto, Helen J Gogas et al. · The Lancet Oncology
Open access |
21 Mar 2018 |
1,040 |
| 28 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R.D. Johnston et al. · Journal of Clinical Oncology
Open access |
20 Sep 2020 |
1,037 |
| 29 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore Bianchi et al. · The Lancet Oncology
Open access |
26 Apr 2016 |
1,032 |
| 30 |
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology
Open access |
29 Sep 2019 |
1,016 |
| 31 |
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Sibylle Loibl et al. · Annals of Oncology
Open access |
13 Dec 2023 |
991 |
| 32 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep M. Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology
|
12 Apr 2015 |
967 |
| 33 |
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Mingzhao Xing et al. · JAMA
Open access |
9 Apr 2013 |
943 |
| 34 |
Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial
Guglielmo Ronco, Paolo Giorgi Rossi, Francesca Carozzi et al. · The Lancet Oncology
|
19 Jan 2010 |
941 |
| 35 |
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Sherene Loi et al. · Journal of Clinical Oncology
Open access |
16 Jan 2019 |
930 |
| 36 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Gabriel N. Hortobágyi et al. · Annals of Oncology
Open access |
25 Apr 2018 |
893 |
| 37 |
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al. · New England Journal of Medicine
Open access |
28 May 2020 |
891 |
| 38 |
Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor
Ilaria Marigo, Erika Bosio, Samantha Solito et al. · Immunity
Open access |
Jun 2010 |
854 |
| 39 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew Xiuxuan Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology
Open access |
18 Jun 2015 |
850 |
| 40 |
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
François‐Clément Bidard et al. · The Lancet Oncology
|
11 Mar 2014 |
848 |
| 41 |
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Alba Ariela Brandes, Enrico Franceschi, Alicia Tosoni et al. · Journal of Clinical Oncology
|
29 Apr 2008 |
842 |
| 42 |
The Terminology Issue for Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich, Vincenzo Bronte, Shu‐Hsia Chen et al. · Cancer Research
Open access |
2007 |
827 |
| 43 |
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina
Shona A. Hendry et al. · Advances in Anatomic Pathology
Open access100 authors |
2 Aug 2017 |
816 |
| 44 |
Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma
Laura Gramantieri, Manuela Ferracin, Francesca Fornari et al. · Cancer Research
Open access |
Jul 2007 |
816 |
| 45 |
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
C. Gridelli et al. · JNCI Journal of the National Cancer Institute
Open access |
4 Mar 2003 |
799 |
| 46 |
Metabolic control of YAP and TAZ by the mevalonate pathway
Giovanni Sorrentino, Naomi Ruggeri, Valeria Specchia et al. · Nature Cell Biology
|
23 Mar 2014 |
795 |
| 47 |
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations
Lore Decoster, Katrien Van Puyvelde, Supriya Gupta Mohile et al. · Annals of Oncology
Open access |
17 Jun 2014 |
794 |
| 48 |
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al. · Nature Medicine
|
29 Jul 2012 |
793 |
| 49 |
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Maddalena Adorno, Michelangelo Cordenonsi, Marco Montagner et al. · Cell
Open access |
Apr 2009 |
790 |
| 50 |
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Giovanna Gallina, Luigi Dolcetti, Paolo Serafini et al. · Journal of Clinical Investigation
Open access |
2 Oct 2006 |
789 |